Immunogenomic characterization of advanced clear cell renal cell carcinoma treated with PD-1 blockade.

David A.  Braun

Honoraria - LM Education/Exchange Service

Consulting or Advisory Role - Adept Field Solutions; Blueprint Partnership; Bristol-Myers Squibb; Charles River Associates; Dedham Group; Defined Health; Insight Strategy; Octane Co.; Schlesinger Associates; Slingshot Insights; Trinity Group

Travel, Accommodations, Expenses - Bristol-Myers Squibb

Yue  Hou

No Relationships to Disclose

Ziad  Bakouny

Research Funding - Bristol-Myers Squibb (Inst)

Miriam  Ficial

No Relationships to Disclose

Miriam  Sant'Angelo

No Relationships to Disclose

Petra  Ross-Macdonald

Employment - Bristol-Myers Squibb

Stock and Other Ownership Interests  - Bristol-Myers Squibb; Merck

Research Funding - Bristol-Myers Squibb

Patents, Royalties, Other Intellectual Property - Bristol-Myers Squibb

Opeyemi  Jegede

No Relationships to Disclose

Maxine  Sun

No Relationships to Disclose

Megan  Wind-Rotolo

Employment - ApotheCom; Bristol-Myers Squibb

Stock and Other Ownership Interests  - Bristol-Myers Squibb

Jean-Christophe  Pignon

Employment - Pyramid Consulting Group

Donna S.  Neuberg

Stock and Other Ownership Interests  - Madrigal Pharmaceuticals

Research Funding - Pharmacyclics

Paul J.  Catalano

No Relationships to Disclose

Gordon J.  Freeman

Honoraria - Bristol-Myers Squibb

Consulting or Advisory Role - Adaptimmune (I); Elpiscience (I); Elstar Therapeutics (I); ITeos Therapeutics; Jubilant Therapeutics; Monopteros Therapeutics (I); Monopteros Therapeutics (I); Nextpoint; Origimed; Selecta Biosciences (I); SQZ Biotech (I); Surface Oncology (I); Triursus Therapeutics; Xios Therapeutics

Research Funding - Bristol-Myers Squibb; Ipsen (I); Merck Sharp & Dohme (I); Novartis (I); Quark (I); Roche/Genentech (I); UCB (I)

Patents, Royalties, Other Intellectual Property - Amplimmune/Astrazeneca; Boehringer Ingelheim; Bristol-Myers Squibb/Medarex; Dako; EMD Serono; Leica Biosystems; Mayo Clinic; Merck; Novartis; Novartis (I); Pfizer (I); Pfizer (I); Roche/Genentech; Roche/Genentech (I)

Arlene  Sharpe

Consulting or Advisory Role - Adaptimmune; Bristol-Myers Squibb; Elpiscience; Elstar Therapeutics; igm; ITeos Therapeutics; Jubilant Biosys; Monopteros Therapeutics; NextPoint; Origimed; Roche; Selecta Biosciences; SQZ Biotech; Surface Oncology; Triursus Therapeutics; Xios Therapeutics

Research Funding - Bristol-Myers Squibb; Ipsen; Merck; Novartis; Quark; Roche; UCB

Patents, Royalties, Other Intellectual Property - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; DAKO; Leika; Mayo Clinic; Merck; Merck Serono; Novartis; Pfizer; Roche

Other Relationship - Journal of Experimental Medicine

(OPTIONAL) Uncompensated Relationships - Novartis

David F.  McDermott

Consulting or Advisory Role - alkermes; Array BioPharma; Bristol-Myers Squibb; EMD Serono; exelixis; Genentech/Roche; Jounce Therapeutics; Lilly; Merck; Novartis; Peloton Therapeutics; Pfizer

Research Funding - alkermes (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Prometheus (Inst)

Other Relationship - Beth Israel Deaconess Medical Center

(OPTIONAL) Uncompensated Relationships - AVEO; X4 Pharma

Eliezer Mendel  Van Allen

Stock and Other Ownership Interests  - ervaxx; Genome Medical; Microsoft; Syapse; Tango Therapeutics

Consulting or Advisory Role - ervaxx; Genome Medical; Illumina; InVitae; Janssen; Novartis; Roche; Syapse; Takeda; Tango Therapeutics; Third Rock Ventures

Speakers' Bureau - Illumina

Research Funding - Bristol-Myers Squibb; Novartis

Patents, Royalties, Other Intellectual Property - Patent on clinical interpretation algorithms using cancer molecular data (Inst); Patent on discovery of chromatin regulators as biomarkers of response to cancer immunotherapy (Inst); Patent on discovery of retained intron as source of cancer neoantigens (Inst)

Travel, Accommodations, Expenses - Roche/Genentech

Sabina  Signoretti

Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Merck

Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Novartis (Inst)

Patents, Royalties, Other Intellectual Property - Receives royalties from Biogenex

Other Relationship - AACR; NCI

Catherine J.  Wu

Stock and Other Ownership Interests  - Neon Therapeutics; Neon Therapeutics (I)

Research Funding - Pharmacyclics

Patents, Royalties, Other Intellectual Property - Neon Therapeutics; Neon Therapeutics (I)

Sachet A.  Shukla

Stock and Other Ownership Interests  - Agenus; Agios; BreakBio Corp.; Bristol-Myers Squibb; Newlink Genetics

Patents, Royalties, Other Intellectual Property - Dana-Farber Cancer Institute

Toni K.  Choueiri

Employment - Dana Farber Cancer Hospital

Leadership - ASCO; Dana Farber Cancer Hospital; Kidney Cancer Association; KidneyCan; NCCN

Stock and Other Ownership Interests  - Pionyr; Tempest Therapeutics

Honoraria - Alexion Pharmaceuticals; alligent; Analysis Group; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; Exelixis; Foundation Medicine; Genentech/Roche; GlaxoSmithKline; Harborside Press; HERON; Ipsen; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Sanofi/Aventis; The New England Journal of Medicine; UpToDate

Consulting or Advisory Role - Alexion Pharmaceuticals; alligent; Analysis Group; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; GlaxoSmithKline; Harborside Press; HERON; Ipsen; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Roche/Genentech; Sanofi/Aventis; The New England Journal of Medicine; UpToDate

Research Funding - Agensys (Inst); Analysis Group (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); Cerulean Pharma (Inst); Congressionally Directed Medical Research Programs (DOD) (Inst); Corvus Pharmaceuticals (Inst); Eisai (Inst); Exelixis (Inst); Foundation Medicine (Inst); Gateway for Cancer Research (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Merck (Inst); NCI (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Prometheus (Inst); Roche (Inst); Roche/Genentech (Inst); Seattle Genetics/Astellas (Inst); Takeda (Inst); TRACON Pharma (Inst)

Patents, Royalties, Other Intellectual Property - -International Patent Application No. PCT/US2018/058430, entitled “Biomarkers of Clinical Response and Benefit to Immune Checkpoint Inhibitor Therapy; International Patent Application No. PCT/US2018/12209, entitled “PBRM1 Biomarkers Predictive of Anti-Immune Checkpoint Response

Travel, Accommodations, Expenses - Alexion Pharmaceuticals; alligent; Analysis Group; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; GlaxoSmithKline; Harborside Press; HERON; Ipsen; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Roche/Genentech; Sanofi/Aventis; The New England Journal of Medicine; UpToDate

Other Relationship - Medical writing and editorial assistance support may have been funded by Communications companies funded by pharmaceutical companies such as ClinicalThinking, Health Interactions, Envision Pharma Group, Fishawack Group of Companies, Parexel